Insilico Medicine Applauded by Frost & Sullivan for Enabling Rapid and Cost-Effective Drug Discovery and Development with Its Pharma.AI Platform
The Pharma.AI platform combining deep generative models (GAN), reinforcement learning (RL), transformers, and other modern machine learning techniques enables the identification of novel targets, generation of novel molecules non-existent in the chemical space, and prediction of outcomes for clinical trials. SAN ANTONIO, Jan. 25, 2022 /PRNewswire/ -- Based on its recent analysis of the global artificial intelligence (AI)-enabled drug discovery industry, Frost &...
SyMap Medical Ltd Completed Enrollment in SMART Study for the Treatment of Uncontrolled Hypertension
SUZHOU, China, Feb. 23, 2022 /PRNewswire/ -- SyMap Medical Ltd. (Suzhou, China) announced successful completion of enrollment in the company's SMART Study (Sympathetic Mapping/Ablation Renal nerves for Treatment of hypertension Trial; NCT02761811), using the SyMapCath I™ Catheter/SYMPIONEER S1™ Mapping/RF System for the treatment of uncontrolled hypertension. This is the first pivotal...
Firmenich Receives SBTi Approval For Net-Zero Emissions Target
Firmenich is the first company in the industry to receive approval from the Science Based Targets initiative (SBTi) for its net-zero emissions target GENEVA, Aug. 23, 2022 /PRNewswire/ -- Firmenich, the world's largest privately-owned fragrance and taste company, has received approval from the Science Based Targets initiative (SBTi) for its net-zero emissions...
QureBio Ltd. to Present its Q-1802 Clinical Phase Ⅰ Data at 2023 ASCO-GI Meetings
SHANGHAI, Dec. 21, 2022 /PRNewswire/ -- QureBio Ltd., a clinical-stage biopharmaceutical company focusing on development of bispecific antibodies and other engineered Biopharmaceuticals for the treatment of cancer, inflammation, and other serious disorders, today announced that Phase Ⅰ Clinical Data of its Q-1802 program will be presented at ASCO Gastrointestinal Cancers Symposium (ASCO-GI) hold at the San Francisco and online...
Senhwa Presents Positive Initial Data from Phase 2 Clinical Trial of Silmitasertib (CX-4945) in Moderate COVID-19 Patients At the ISIRV-WHO Conference
Statistically significant 133% faster time to COVID-19 clinical symptoms recovery versus standard of care (SOC)/best supportive care. Statistically significant 114% faster time to reach EQ-5D-5L Q6 ≥ 90% versus SOC/best supportive care. Statistically significant 57% faster time to normalization of COVID-19 related clinical signs versus SOC/best supportive care. ...
Qilian International Holding Group Limited Announces Inclusion of Gan Di Xin® and Qilian Shan® Oxytetracycline into List for Development of Leading Enterprises with Large Varieties and Brands of Pharmaceuticals...
JIUQUAN, China, Nov. 23, 2021 /PRNewswire/ -- Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company"), a China-based pharmaceutical and chemical products manufacturer, today announced that Gan Di Xin® and Qilian Shan® Oxytetracycline, products of the Company's subsidiary, Gansu Qilianshan Pharmaceutical Co., Ltd. ("Gansu QLS"), have been included in the List for Development of Leading Enterprises with Large Varieties...
Biotron Drug Effective Against COVID-19 In Animals
BIT225 administered orally significantly reduced viral load in the lungs and blood of animals challenged with SARS-CoV-2. BIT225 protected against severe disease, indicated by the significant prevention of body weight loss in animals treated with BIT225 compared to non-treated controls. Pro-inflammatory cytokines were also significantly reduced in the lungs and blood of BIT225 treated animals compared...
CRI Online: China’s Fangchenggang City Hosts 2021 IMICF
FANGCHENGGANG, China, Dec. 8, 2021 /PRNewswire/ -- A news reported by CRI Online: On December 6, the 2021 International Medical Innovation Cooperation Forum was held in Fangchenggang City, Guangxi Province online and offline. The scene of the 2021 International Medical Innovation Cooperation Forum This forum will play an important role in promoting the high-quality development of...
MHI RJ Aviation Group and Aero HygenX sign a cooperation agreement for Marketing and Distribution of RAY UV-C Robot
MHIRJ, the largest Regional MRO in the world, to market RAY product line to CRJ Series operators RAY UV-C Robot disinfection reduces potential negative impact on aircraft interiors and sensitive equipment Both RAY and the CRJ Series aircraft are proudly Canadian products OTTAWA, ON, Dec. 10, 2021 /PRNewswire/ -- Aero HygenX, makers of the "RAY"...
New NCCN Guidelines help Patients Better Understand and Participate in the Care of their Cervical Cancer
The free resource, available at NCCN.org/patientguidelines, helps patients know what to expect and participate actively in decisions about their care. PLYMOUTH MEETING, Pa., Dec. 14, 2021 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) has published new NCCN Guidelines for Patients®: Cervical Cancer to help people with cervical cancer become more informed, suggest what...
